Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with <em>BRAF</em>V600E-mutant metastatic colorectal cancer.
Axel Grothey, MD, medical oncologist, Department of Oncology, Mayo Clinic, discusses the role of sidedness in tumor location in colorectal cancer.
Axel Grothey, MD, Mayo Clinic in Rochester, Minnesota, discusses the Lume 1 and 2 trials as well as new treatment options for metastatic colorectal cancer.
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.
Published: September 1st 2016 | Updated:
Published: January 24th 2019 | Updated:
Published: July 10th 2015 | Updated:
Published: July 12th 2016 | Updated: